High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. - Wikidata - awgldk - TriplyDB

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

http://www.wikidata.org/entity/Q37109358

about

Mutant HRAS as novel target for MEK and mTOR inhibitors Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia RAS oncogenes: weaving a tumorigenic web RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.Clinical proteomics of myeloid leukemia.Genomic and biological characterization of exon 4 KRAS mutations in human cancer BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Induction of histiocytic sarcoma in mouse skeletal muscle.Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Our changing view of the genomic landscape of cancer.Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.Targeting oncogenic Ras signaling in hematologic malignancies.A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.N-ras mutation detection by pyrosequencing in adult patients with acute myeloid leukemia at a single institution Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.Current status of allogeneic HST for chronic myelomonocytic leukemia.Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.Genomic tools in acute myeloid leukemia: From the bench to the bedside Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms Genomic determinants of chronic myelomonocytic leukemia.Identification of an oncogenic RAB protein.

P2860

Q27853238-9F2CBE2A-0CE5-4B45-B93A-57334C16D117 Q28236628-BD3F9636-A1AE-4F0F-9F6C-9268B44FE825 Q28250360-167C3333-7CC7-4B6D-9FD6-C76DFEB57044 Q30967175-41030018-93CC-4CBF-A3F5-D83DC51A384C Q33555627-DA397025-D210-4368-A39B-93E2C149B2CB Q33583033-22EF7C94-33A9-4E36-AD8C-3C90168152F2 Q33622710-550FC861-F232-4DE6-BA46-CB32A5138521 Q33723645-048E7262-118B-4933-99F4-BFE9E75FE8B7 Q33754040-C48AA01C-8841-485E-8C07-4044FDB0B697 Q33871210-F33DBB04-9555-4624-AC49-1A701A70E57B Q33999524-0FBAB23A-AA42-492D-8A44-326D2784B9B8 Q34145806-43A1EA14-1D3B-4D33-80A0-C070F15B3E96 Q34393208-CFD8765A-3431-4281-8C9D-9A9FC69504D2 Q34406138-C8E5CA81-1404-4E5C-B882-859F474C71ED Q34438500-C7F5C659-6832-4233-B8EE-A0743B6FDD82 Q34465221-A3B5E216-9FCE-4C9A-B22C-D5F9CC841454 Q34631111-FCAEFC4C-743A-4C84-A067-CFEC8EBCA690 Q34638143-3E067F43-008A-4111-AA17-A330F7D7E057 Q35128725-0E5CB31D-0061-44C1-B433-386BBC5CFD5A Q35346433-20B994A4-5CD6-458F-9055-9E9B72FE4BC8 Q35368205-E25DB0D1-F9C8-439C-9549-0870A580049D Q35610140-567ACA55-9D2C-40F5-A813-284A0B86D6A5 Q35674250-3FD89B7C-9646-49AF-AAC8-EDBA546F3918 Q36293540-91ED0791-5BCE-4FA2-B087-E12B4981974F Q36352506-3D153C36-F0BD-450F-AFA2-330F0A826649 Q36608758-9C8768FF-6DD1-4A27-8415-DA8925116D53 Q36821796-7AA76B91-B04E-49C8-B254-D5C8B2A4ED7F Q36984831-29CE79F7-BE0B-4BA7-AF19-B48ED96D8386 Q37109905-4364CB02-0FF5-4BC5-9D13-0419627FE33F Q37362603-EB509800-644C-4569-A8CE-733B9B4DB5BA Q37470906-FF42F0D6-774A-4425-B614-10D76BE0A84E Q37644854-106C6914-1AAA-4E68-B632-A6A657700364 Q37899751-7CDBECBE-4D8A-442F-AFEC-2063A5EC82F7 Q37993420-0FDC8054-E349-4642-8588-BFEA796E082E Q38044773-66427D6C-2C17-4094-91FC-689D81CBF3DF Q38106675-370F204E-7CAD-474E-A09A-997CC61F5435 Q38182932-24C5485D-6546-43E8-992C-77BFAD288FF8 Q38344558-7B3B352B-832D-4A7F-BEB1-64AD34929616 Q38757999-2B17FBDB-1869-4E81-B2F0-4157CA18CCCF Q38838098-59DDCB73-86E5-4854-80CA-BA14761D0321

P2860

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

http://www.wikidata.org/entity/Q37109358

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

High-throughput sequencing scr ...... in myeloid leukemia patients.

@en

High-throughput sequencing scr ...... in myeloid leukemia patients.

@nl

type

label

High-throughput sequencing scr ...... in myeloid leukemia patients.

@en

High-throughput sequencing scr ...... in myeloid leukemia patients.

@nl

prefLabel

High-throughput sequencing scr ...... in myeloid leukemia patients.

@en

High-throughput sequencing scr ...... in myeloid leukemia patients.

@nl

P1433

Q37109358-6A09308B-4F28-44F1-B656-ED7353EB9215

P1476

Q37109358-8092802F-D8F8-4077-9026-9EC68213FE65

P2093

Q37109358-1699DE61-6DB0-4B2E-821F-D6BB5F4C6EE7

Q37109358-3AB49799-FDE7-4DC5-A63E-C44798C0C355

Q37109358-561BD5FC-1D00-4DAA-8E7D-37B44158535E

Q37109358-6017608E-45BE-4BCF-872B-ACD3482BA521

Q37109358-D5CE8068-0366-4299-A004-6FC430345FA9

Q37109358-D8159315-9922-4FE9-82A5-5D4F314D0BB2

Q37109358-E9988198-9B4D-40F4-BD93-F12B20413841

P2860

Q37109358-2C0B05F1-2EC2-474C-B827-2F319CECDC43

Q37109358-30E5C865-5004-43EF-B61A-20B5B9A160B1

Q37109358-37DBBE3A-1A70-477D-A601-E33E1FDC9689

Q37109358-4C987979-0605-421F-82C0-3EE4B395F6A2

Q37109358-58D6A86C-B677-4E0A-B7E0-AA38A3A7AA4E

Q37109358-65B22B02-6637-4072-821E-65F36AFC9E37

Q37109358-72F56225-C957-47B6-8D03-C1898F7CFB15

Q37109358-7317DF78-504E-4D05-8ED3-1D3C0B1B9C9A

Q37109358-756301E9-5858-453E-B9C5-1F18C83EA178

Q37109358-7A4A05E2-18F2-462F-BD07-CB6C3F008968

P304

Q37109358-A3A2027B-2444-448F-B608-ECD822C1A8B8

P31

Q37109358-B5D965F6-6655-45DD-A7E0-9CF87BBAFB69

P356

Q37109358-D6117EA5-6C77-46AB-A695-74A4B7163277

P407

Q37109358-18DDE2FD-3C74-47FC-9D35-F3ABA6A77DC5

P433

Q37109358-22678333-3E3C-4231-B54A-653A21F7BA3C

P478

Q37109358-2075E5BC-3F79-4931-AAFE-83CBE96D92C8

P50

Q37109358-ADC8186C-582B-4E9C-8254-B1724422F16E

Q37109358-C2389480-00BE-411E-B4EB-E34A7DD25BEC

Q37109358-D20F6C5C-F48C-41A3-B462-8A7446ABC3C3

Q37109358-DE4BF84B-7981-4399-A34F-06209B7E0B5B

P577

Q37109358-FD688B1F-AE6E-4800-AD78-F7359CF7D907

P5875

Q37109358-1D315B58-559F-444B-A160-65537D74FD81

P698

Q37109358-EBF1E33B-CA1F-4097-93CF-6283C99F4E56

P921

Q37109358-4FB30CC0-9EF9-4479-B0B9-2CE86BE39077

Q37109358-5553366E-2300-44DC-B0FA-E7A337680923

P932

Q37109358-B7E0AD6C-4DD2-403B-8113-E2E40B28B730

P356

BLOOD-2008-04-152157

P1433

P1476

High-throughput sequencing scr ...... in myeloid leukemia patients.

@en

P2093

Christopher A Eide

http://www.w3.org/2001/XMLSchema#string

D Gary Gilliland

http://www.w3.org/2001/XMLSchema#string

Heidi Erickson

http://www.w3.org/2001/XMLSchema#string

Marc M Loriaux

http://www.w3.org/2001/XMLSchema#string

Michael W N Deininger

http://www.w3.org/2001/XMLSchema#string

Ross L Levine

http://www.w3.org/2001/XMLSchema#string

Stephanie G Willis

http://www.w3.org/2001/XMLSchema#string

P2860

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

The consensus coding sequences of human breast and colorectal cancers

Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

Germline KRAS mutations cause Noonan syndrome

Nf1 and Gmcsf interact in myeloid leukemogenesis

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

ras oncogenes in human cancer: a review

Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins.

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

P304

1749-1755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-04-152157

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Brian J. Druker

Michael C. Heinrich

Jeffrey W. Tyner

Norbert Gattermann

P577

2008-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23656088

http://www.w3.org/2001/XMLSchema#string

P698

19075190

http://www.w3.org/2001/XMLSchema#string

P921

P932

2647674

http://www.w3.org/2001/XMLSchema#string